Skip to main
PTGX
PTGX logo

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 62%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc. demonstrates a promising outlook due to the positive clinical response trends observed in their key pipeline product, icotrokinra, which showed a 5-7% improvement in clinical response from week 12 to 28, indicating robust long-term efficacy. Additionally, the data reveals significant endoscopic improvement rates and high levels of disease clearance in difficult-to-treat areas, setting a strong foundation for market uptake upon its anticipated launch following the NDA submission in July 2025. Furthermore, the company's established track record in business development and expected momentum through key catalysts in 2025 reinforces a favorable position for continued growth and advancement within the biopharmaceutical market.

Bears say

Protagonist Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, highlighted by concerns regarding potential safety issues in ongoing clinical trials and the possibility that strategic partners may refrain from further developing its key product icotrokinra, due to competitive pressures. Additionally, the company is exposed to heightened regulatory and pricing risks, particularly given the evolving landscape in the orphan drug market, which may impact future profitability and market access. Coupled with these factors is the looming threat of dilution stemming from future cash needs, which could further impact shareholder value in the volatile biopharmaceutical sector.

Protagonist Therapeutics (PTGX) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 62% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 13 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.